scholarly journals B-cell epitope KT-12 of enterohemorrhagic Escherichia coli O157:H7: a novel peptide vaccine candidate

2011 ◽  
Vol 55 (4) ◽  
pp. 247-253 ◽  
Author(s):  
Cheng-song Wan ◽  
Yong Zhou ◽  
Yang Yu ◽  
Li juan Peng ◽  
Wei Zhao ◽  
...  
2008 ◽  
Vol 22 (S1) ◽  
Author(s):  
Xu‐Hu Mao ◽  
Shu Yu ◽  
Jiang Gu ◽  
Qingxu Wang ◽  
Quanï¼□ming Zou

2021 ◽  
Vol 10 (1) ◽  
pp. 06-13
Author(s):  
Viol Dhea Kharisma ◽  
Arif Nur Muhammad Ansori ◽  
Gabrielle Ann Villar Posa ◽  
Wahyu Choirur Rizky ◽  
Sofy Permana ◽  
...  

Acquired immune deficiency syndrome (AIDS) has been identified from US patients since 1981. AIDS is caused by infection with the human immunodeficiency virus type 1 (HIV-1) which is a retrovirus. HIV-1 gp120 can be recognized by the immune system because it is located outside the virion. The conserved region is identified in gp120, and it is recognized by an immune cell which then initiates specific immune responses, viral mutation escape, and increase vaccine protection coverage, a benefit derived from the conserved region-based vaccine design. However, previous researchers have little knowledge on this conserved region as a target for vaccine design. This paper explains how the conserved region of gp120 HIV-1 is a major target for vaccine design through a bioinformatics approach. The conserved region from gp120 was explored as a vaccine design target with a bioinformatics tool that consists of B-cell epitope mapping, vaccine properties, molecular docking, and dynamic simulation. The peptide vaccine candidate of B5 with the gp120 HIV-1 conserved region was found to provoke B-cell activation through a direct pathway, produce specific antibody, and increase protection from multi-strain viral infection.


2014 ◽  
Vol 192 (12) ◽  
pp. 5813-5820 ◽  
Author(s):  
Esther D. Quakkelaar ◽  
Marieke F. Fransen ◽  
Wendy W. C. van Maren ◽  
Joost Vaneman ◽  
Nikki M. Loof ◽  
...  

Immunity ◽  
2004 ◽  
Vol 21 (5) ◽  
pp. 617-627 ◽  
Author(s):  
Ara G. Hovanessian ◽  
Jean-Paul Briand ◽  
Elias A. Said ◽  
Josette Svab ◽  
Stephane Ferris ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. e0146951 ◽  
Author(s):  
Rodrigo Nunes Rodrigues-da-Silva ◽  
João Hermínio Martins da Silva ◽  
Balwan Singh ◽  
Jianlin Jiang ◽  
Esmeralda V. S. Meyer ◽  
...  

2020 ◽  
Author(s):  
Arwa A. Mohammed ◽  
Mayada E. Elkhalifa ◽  
Khadija E. Elamin ◽  
Rawan A. Mohammed ◽  
Musab E. Ibrahim ◽  
...  

AbstractBackgroundLujo virus (LUJV) is a highly fatal human pathogen belonging to the Arenaviridae family. Lujo virus causes viral hemorrhagic fever (VHF). An In silico molecular docking was performed on the GPC domain of Lujo virus in complex with the first CUB domain of neuropilin-2.The aim of this study is to predict effective epitope-based vaccine against glycoprotein GPC precursor of Lujo virus using immunoinformatics approaches.Methods and Materialsglycoprotein GPC precursor of Lujo virus Sequence was retrieved from NCBI. Different prediction tools were used to analyze the nominee’s epitopes in BepiPred-2.0: Sequential B-Cell Epitope Predictor for B-cell, T-cell MHC class II & I. Then the proposed peptides were docked using Autodock 4.0 software program.Results and ConclusionsThe proposed and promising peptides FWYLNHTKL and YMFSVTLCI shows a very strong binding affinity to MHC class I & II alleles with high population coverage for the world, South Africa and Sudan. This indicates a strong potential to formulate a new vaccine, especially with the peptide YMFSVTLCI which is likely to be the first proposed epitope-based vaccine against glycoprotein GPC of Lujo virus. This study recommends an in-vivo assessment for the most promising peptides especially FWYLNHTKL, YMFSVTLCI and LPCPKPHRLR.


2012 ◽  
Vol 56 (04) ◽  
pp. 337-342 ◽  
Author(s):  
KEE-BUM PARK ◽  
BYUNG-KWAN LIM ◽  
MICHAEL B. YE ◽  
SOO-YOUNG CHUNG ◽  
JAE-HWAN NAM

Sign in / Sign up

Export Citation Format

Share Document